GH axis Research Market

GHRP-2

A growth hormone secretagogue that appears in older GH-optimization discussions and research-market listings.

Growth HormoneSecretagogueResearch Market

Also appears in: Performance

Vial price compare
24 tracked offers across 24 vendors · 5 dosages
Best trust-adjusted value: Peptuvia · Strong trust · $0.54/mg
From
$0.54/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

-10.0% vs. Sep 6
Current low$0.54/mg
Market median$3.59/mg
Current coverage18 vendors
Observed window90 daily points
Lowest effective price Market median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when GHRP-2 crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence 12 certificate records for GHRP-2 products, from 8 vendors 5 reference a report on the testing laboratory's own system · 2 have a laboratory lookup that answered when last checked · 12 match a vendor product page at the same address
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
GH axis / secretagogue research

Primary research area: GH axis. Also surfaces under Performance for browsing and discovery.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Low

No FDA label signal · 0 trials · 205 PubMed results

Preclinical
Research evidence

Current evidence for GHRP-2 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

GHRP-2 has no clinical trials that name it and 205 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
High-impact
American Journal of Physiology-Endocrinology and Metabolism · 173 citations Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats Peptides · 88 citations Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH Journal of Endocrinology · 65 citations The Effect of GH-Releasing Peptide-2 (GHRP-2 or KP 102) on GH Secretion from Primary Cultured Ovine Pituitary Cells Can be Abolished by a Specific GH-Releasing Factor (GRF) Receptor Antagonist Journal Article Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests. Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Journal Article Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-03 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What GHRP-2 is

GHRP-2 is one of the older growth hormone secretagogues that helped define the GH-focused peptide niche before the current metabolic-drug wave took over most attention.

Why it matters

It provides context for how the peptide market evolved. Many modern GH stacks and blends still reference earlier secretagogue-era compounds like GHRP-2.

Regulatory context

GHRP-2 is not an FDA-approved GH optimization treatment in the United States and should be read as a research-market profile.

Practical reading note

When comparing GH-related peptides, it helps to distinguish between branded medical therapies, diagnostic tools, and research-market secretagogues.